Supplementary Figures S1-8 from Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia
Shellaina J.V. Gordon(The University of Melbourne), Mark A. Dawson(The University of Melbourne), Kathy Knezevic(Peter MacCallum Cancer Centre), Yih-Chih Chan(The University of Melbourne), Jakub Horvath(The University of Melbourne), Scott A. Armstrong(Courant Institute of Mathematical Sciences), Daniela V. Wenge(Dana-Farber Cancer Institute), Brendon J. Monahan(Monash University), Dane Vassiliadis(The University of Melbourne), Michelle A. Camerino(Monash University), Wallace Bourgeois(NYU Langone Health), John D. Lapek(University of Rochester Medicine), Ian P. Street(Unknown), Xinmeng Jasmine Mu(Pfizer (United States)), Enid Y.N. Lam(The University of Melbourne), Jesse J. Balic(Hudson Institute of Medical Research), Thomas A. Paul(Pfizer (United States)), Henrietta Holze(The University of Melbourne), Ylva E. Bozikis(Monash University), Paul A. Stupple(Monash University), Andrea Gillespie(National Institutes of Health), Florian Perner(Medizinische Hochschule Hannover), Sean Uryu(Pfizer (United States)), Elanor N. Wainwright(Peter MacCallum Cancer Centre), Benjamin J. Blyth(Peter MacCallum Cancer Centre), Ahmet Murat(Medizinische Hochschule Hannover), Joan Cao(Pfizer (United States)), Jeffrey R. White(Pfizer (United States)), Thomas Plenge(Medizinische Hochschule Hannover), Tabea Klaus(Medizinische Hochschule Hannover), Katie Fennell(Peter MacCallum Cancer Centre), Jelena Petrovic(Pfizer (United States)), Laura MacPherson(Natural Resources Canada)
Cited by 0
Related Papers
The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease
|Science|2006|5.5k
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
|Nature|2011|1.5k
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
|Cell Reports|2016|936